Gansu Longshenrongfa Pharmaceutical Industry Co 300534.SZ · CNY
Health Care · Shenzhen · 🇨🇳 China
10.22
+3.44%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Gansu Longshenrongfa Pharmaceutical Industry Co
Its shares trade on Shenzhen under the ticker 300534.SZ. It has been listed since 13 September 2016. In the fiscal year to 31 December 2025, it reported revenue of CN¥887.0m and net income of CN¥44.0m. At that date it held total assets of CN¥1.39bn and shareholders' equity of CN¥708.5m.
Gansu Longshenrongfa Pharmaceutical Industry Co., Ltd. engages in the research, development, and sale of medical and healthcare products. The company is headquartered in Lanzhou, Gansu. The company went IPO on 2016-09-13. The firm operates two segments. The Pharmaceutical Manufacturing segments is involved in the production and sale of Chinese traditional medicine, health food and raw materials. Its primary product is Yuanhuzhitong dripping pills, which is used for the treatment of stomach pain, rib pain and headache. The firm also produces other drugs, including compound salvia miltiorrhiza tablets, anti-inflammatory and gallbladder tablets, as well as Sanqi injury tablets. The Sales and Logistics segment operates logistics and distribution business.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 13 Sept 2016
- Employees
- 320
- Website
- lsrfzy.com ↗
Leadership
Pay as last reported
- Mr. Yonghong KangChairman of the Board, since 2011CN¥252,100
- Ms. Rong XiaoChief Financial Officer
- Ms. Yuehong SongGeneral Manager, Chief Engineer, Director, since 2024
- Mr. Qinhui YuanDeputy General Manager, Secretary of the Board, Director, since 2012CN¥241,200
- Mr. Wenliang ChenDeputy General Manager
- Mr. Bo SunDeputy General Manager
- Mr. Rui FuDirector
- Mr. Kaicai ZhuDirector, since 2024
- Mr. Zongyi LiIndependent DirectorCN¥45,000
- Mr. Zhen LuoIndependent DirectorCN¥45,000
- Ms. Ye WuIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- The company employs 320 full-time staff members in Lanzhou.
- Yuanhuzhitong dripping pills treat stomach pain and rib pain effectively.
- The firm produces compound salvia miltiorrhiza tablets for health care.
Weaknesses
- The company operates only two business segments currently.
- Sales and logistics rely on internal distribution capabilities.
- Chinese traditional medicine faces intense market competition pressures.
Opportunities
- Expanding the sale of health food products globally.
- Increasing production of raw materials for pharmaceutical use.
- Growing demand for anti-inflammatory and gallbladder tablets.
Threats
- Regulatory changes in the Chinese pharmaceutical market.
- Fluctuating prices for traditional medicine raw materials.
- New competitors entering the Lanzhou healthcare sector.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.